PMID- 34914338
OWN - NLM
STAT- MEDLINE
DCOM- 20220928
LR  - 20220928
IS  - 2191-0286 (Electronic)
IS  - 0792-6855 (Linking)
VI  - 33
IP  - 5
DP  - 2022 Sep 1
TI  - Effect of ascorbic acid supplementation on pulmonary functions in healthy adults: 
      a randomized controlled pilot study.
PG  - 625-632
LID - 10.1515/jbcpp-2021-0243 [doi]
AB  - OBJECTIVES: The fact that oxidative stress plays an important role in the 
      pathogenesis of various pulmonary diseases is supported by the beneficial effect 
      of antioxidants. It is also well known that an altered oxidant-antioxidant 
      balance after the age of 35 years increases the susceptibility to develop 
      obstructive lung diseases later in life. Given this, the present study was 
      designed to evaluate the effect of antioxidant supplementation on lung functions 
      in healthy adults after the age of 35 years. METHODS: Persons of age >/=35 years 
      (n=45) were randomized into three arms (each comprising 15 participants) to 
      receive either no intervention (NI arm), ascorbic acid 250 mg daily (AA250 arm), 
      or ascorbic acid 500 mg daily (AA500 arm) for 6 weeks. Forced vital capacity 
      (FVC), forced expiratory volume in 1 s (FEV1), FEV1/FVC, and peak expiratory flow 
      (PEF) were measured at baseline and 6 weeks. Persons of age group (20-30 years) 
      were also enrolled in the study to compare their lung functions and 
      cardiovascular parameters at baseline with those >/=35 years of age. All the 
      adverse events experienced by participants were recorded. RESULTS: Baseline 
      pulmonary functions were found to be comparable among the three study arms and 
      compared to >/=35 years age group, these parameters were found to be better in the 
      younger age group (20-30 years). Most of the pulmonary functions were comparable 
      among the three study arms at 6 weeks. A significant improvement in PEF and % 
      predicted PEF was noted in AA250 arm when compared to baseline values (p=0.049 
      and 0.026, respectively) and in participants with normal pulmonary functions when 
      compared to those with reduced functions at baseline (p=0.059 and p=0.037). 
      CONCLUSIONS: Although ascorbic acid did not affect most of the pulmonary 
      functions in healthy adults, it improved PEF and % predicted PEF at a daily dose 
      of 250 mg. In this regard, it was found effective in individuals with normal 
      pulmonary indices at baseline.
CI  - (c) 2021 Walter de Gruyter GmbH, Berlin/Boston.
FAU - Maharshi, Vikas
AU  - Maharshi V
AUID- ORCID: 0000-0003-0218-3325
AD  - Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Kumar, Vijay L
AU  - Kumar VL
AD  - Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Sarangi, Sudhir C
AU  - Sarangi SC
AD  - Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Dutt Upadhyay, Ashish
AU  - Dutt Upadhyay A
AD  - Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Kumar, Arvind
AU  - Kumar A
AD  - Department of Medicine, All India Institute of Medical Sciences, New Delhi.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20211216
PL  - Germany
TA  - J Basic Clin Physiol Pharmacol
JT  - Journal of basic and clinical physiology and pharmacology
JID - 9101750
RN  - 0 (Antioxidants)
RN  - 0 (Oxidants)
RN  - PQ6CK8PD0R (Ascorbic Acid)
SB  - IM
MH  - Adult
MH  - *Antioxidants
MH  - *Ascorbic Acid/pharmacology
MH  - Dietary Supplements
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Lung
MH  - Oxidants
MH  - Pilot Projects
MH  - Vital Capacity
MH  - Young Adult
OTO - NOTNLM
OT  - age
OT  - ascorbic acid
OT  - healthy individuals
OT  - oxidative stress
OT  - pulmonary functions
EDAT- 2021/12/17 06:00
MHDA- 2022/09/28 06:00
CRDT- 2021/12/16 12:44
PHST- 2021/08/21 00:00 [received]
PHST- 2021/11/24 00:00 [accepted]
PHST- 2021/12/17 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2021/12/16 12:44 [entrez]
AID - jbcpp-2021-0243 [pii]
AID - 10.1515/jbcpp-2021-0243 [doi]
PST - epublish
SO  - J Basic Clin Physiol Pharmacol. 2021 Dec 16;33(5):625-632. doi: 
      10.1515/jbcpp-2021-0243. eCollection 2022 Sep 1.